Logo
x

Search

Subscribe Now

NANOBIOTIX

NANOBIOTIX Signs a License Agreement with Janssen to Co-Develop and Commercialize NBTXR3

NANOBIOTIX Signs a License Agreement with Janssen to Co-Develop and Commercialize NBTXR3

  • July 10, 2023
Nanobiotix Initiates US Patient Enrollment of P-III Trial (NANORAY-312) for Head and Neck Cancer

Nanobiotix Initiates US Patient Enrollment of P-III Trial (NANORAY-312) for Head and Neck Cancer

  • December 27, 2022
PharmaShots Interview: Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy

PharmaShots Interview: Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy

  • August 10, 2022
PharmaShots Interview: In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can Trigger an Immune Priming Effect

PharmaShots Interview: In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can T...

  • June 15, 2022
PharmaShots Weekly Snapshots (May 10 - 14, 2021)

PharmaShots Weekly Snapshots (May 10 - 14, 2021)

  • May 14, 2021
PharmaShots Weekly Snapshots (Jan 18 - 22, 2021)

PharmaShots Weekly Snapshots (Jan 18 - 22, 2021)

  • January 22, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.